Literature DB >> 26739624

A cellular model to study drug-induced liver injury in nonalcoholic fatty liver disease: Application to acetaminophen.

Anaïs Michaut1, Dounia Le Guillou1, Caroline Moreau2, Simon Bucher1, Mitchell R McGill3, Sophie Martinais1, Thomas Gicquel2, Isabelle Morel2, Marie-Anne Robin1, Hartmut Jaeschke3, Bernard Fromenty4.   

Abstract

Obesity and nonalcoholic fatty liver disease (NAFLD) can increase susceptibility to hepatotoxicity induced by some xenobiotics including drugs, but the involved mechanisms are poorly understood. For acetaminophen (APAP), a role of hepatic cytochrome P450 2E1 (CYP2E1) is suspected since the activity of this enzyme is consistently enhanced during NAFLD. The first aim of our study was to set up a cellular model of NAFLD characterized not only by triglyceride accumulation but also by higher CYP2E1 activity. To this end, human HepaRG cells were incubated for one week with stearic acid or oleic acid, in the presence of different concentrations of insulin. Although cellular triglycerides and the expression of lipid-responsive genes were similar with both fatty acids, CYP2E1 activity was significantly increased only by stearic acid. CYP2E1 activity was reduced by insulin and this effect was reproduced in cultured primary human hepatocytes. Next, APAP cytotoxicity was assessed in HepaRG cells with or without lipid accretion and CYP2E1 induction. Experiments with a large range of APAP concentrations showed that the loss of ATP and glutathione was almost always greater in the presence of stearic acid. In cells pretreated with the CYP2E1 inhibitor chlormethiazole, recovery of ATP was significantly higher in the presence of stearate with low (2.5mM) or high (20mM) concentrations of APAP. Levels of APAP-glucuronide were significantly enhanced by insulin. Hence, HepaRG cells can be used as a valuable model of NAFLD to unveil important metabolic and hormonal factors which can increase susceptibility to drug-induced hepatotoxicity.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acetaminophen; CYP2E1; Hepatotoxicity; Liver; NAFLD; Obesity

Mesh:

Substances:

Year:  2015        PMID: 26739624      PMCID: PMC4904302          DOI: 10.1016/j.taap.2015.12.020

Source DB:  PubMed          Journal:  Toxicol Appl Pharmacol        ISSN: 0041-008X            Impact factor:   4.219


  89 in total

1.  Mechanisms of acetaminophen-induced cell death in primary human hepatocytes.

Authors:  Yuchao Xie; Mitchell R McGill; Kenneth Dorko; Sean C Kumer; Timothy M Schmitt; Jameson Forster; Hartmut Jaeschke
Journal:  Toxicol Appl Pharmacol       Date:  2014-06-03       Impact factor: 4.219

Review 2.  Evolving therapies for non-alcoholic steatohepatitis.

Authors:  Herbert Tilg; Alexander R Moschen
Journal:  Expert Opin Drug Discov       Date:  2014-04-25       Impact factor: 6.098

3.  Involvement of hepatic stellate cell cytoglobin in acute hepatocyte damage through the regulation of CYP2E1-mediated xenobiotic metabolism.

Authors:  Yuga Teranishi; Tsutomu Matsubara; Kristopher W Krausz; Thi T T Le; Frank J Gonzalez; Katsutoshi Yoshizato; Kazuo Ikeda; Norifumi Kawada
Journal:  Lab Invest       Date:  2015-02-16       Impact factor: 5.662

4.  Transcriptional activation of CYP2C9, CYP1A1, and CYP1A2 by hepatocyte nuclear factor 4alpha requires coactivators peroxisomal proliferator activated receptor-gamma coactivator 1alpha and steroid receptor coactivator 1.

Authors:  Celia P Martínez-Jiménez; José V Castell; M José Gómez-Lechón; Ramiro Jover
Journal:  Mol Pharmacol       Date:  2006-08-01       Impact factor: 4.436

Review 5.  Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role.

Authors:  J Aubert; K Begriche; L Knockaert; M A Robin; B Fromenty
Journal:  Clin Res Hepatol Gastroenterol       Date:  2011-06-12       Impact factor: 2.947

Review 6.  Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction.

Authors:  Marcella Martignoni; Geny M M Groothuis; Ruben de Kanter
Journal:  Expert Opin Drug Metab Toxicol       Date:  2006-12       Impact factor: 4.481

7.  The nuclear receptor PXR gene variants are associated with liver injury in nonalcoholic fatty liver disease.

Authors:  Silvia Sookoian; Gustavo O Castaño; Adriana L Burgueño; Tomas Fernández Gianotti; María Soledad Rosselli; Carlos Jose Pirola
Journal:  Pharmacogenet Genomics       Date:  2010-01       Impact factor: 2.089

8.  Human cytochrome P450 2E1 mutations that alter mitochondrial targeting efficiency and susceptibility to ethanol-induced toxicity in cellular models.

Authors:  Seema Bansal; Hindupur K Anandatheerthavarada; Govindaswamy K Prabu; Ginger L Milne; Martha V Martin; F Peter Guengerich; Narayan G Avadhani
Journal:  J Biol Chem       Date:  2013-03-07       Impact factor: 5.157

Review 9.  The natural history of drug-induced liver injury.

Authors:  Einar Björnsson
Journal:  Semin Liver Dis       Date:  2009-10-13       Impact factor: 6.115

Review 10.  Toxicant-associated steatohepatitis.

Authors:  Banrida Wahlang; Juliane I Beier; Heather B Clair; Heather J Bellis-Jones; K Cameron Falkner; Craig J McClain; Matt C Cave
Journal:  Toxicol Pathol       Date:  2012-12-21       Impact factor: 1.902

View more
  17 in total

1.  Toxicological Implications of Mitochondrial Localization of CYP2E1.

Authors:  Jessica H Hartman; Grover P Miller; Joel N Meyer
Journal:  Toxicol Res (Camb)       Date:  2017-03-14       Impact factor: 3.524

2.  High-Fidelity Drug-Induced Liver Injury Screen Using Human Pluripotent Stem Cell-Derived Organoids.

Authors:  Tadahiro Shinozawa; Masaki Kimura; Yuqi Cai; Norikazu Saiki; Yosuke Yoneyama; Rie Ouchi; Hiroyuki Koike; Mari Maezawa; Ran-Ran Zhang; Andrew Dunn; Autumn Ferguson; Shodai Togo; Kyle Lewis; Wendy L Thompson; Akihiro Asai; Takanori Takebe
Journal:  Gastroenterology       Date:  2020-10-08       Impact factor: 22.682

3.  Recapitulating lipid accumulation and related metabolic dysregulation in human liver-derived organoids.

Authors:  Ling Wang; Meng Li; Bingting Yu; Shaojun Shi; Jiaye Liu; Ruyi Zhang; Ibrahim Ayada; Monique M A Verstegen; Luc J W van der Laan; Maikel P Peppelenbosch; Wanlu Cao; Qiuwei Pan
Journal:  J Mol Med (Berl)       Date:  2022-01-20       Impact factor: 4.599

4.  Clinical Characteristics of Patients with Drug-induced Liver Injury.

Authors:  Li-Xia Yang; Cheng-Yuan Liu; Lun-Li Zhang; Ling-Ling Lai; Ming Fang; Chong Zhang
Journal:  Chin Med J (Engl)       Date:  2017-01-20       Impact factor: 2.628

5.  Multimorbidity and polypharmacy in diabetic patients with NAFLD: Implications for disease severity and management.

Authors:  Preya Janubhai Patel; Kelly Lee Hayward; Rathiga Rudra; Leigh Ula Horsfall; Fabrina Hossain; Suzanne Williams; Tracey Johnson; Nigel Neil Brown; Nivene Saad; Andrew Donald Clouston; Katherine Anne Stuart; Patricia Casarolli Valery; Katharine Margaret Irvine; Anthony William Russell; Elizabeth Ellen Powell
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

6.  Role of nonalcoholic fatty liver disease as risk factor for drug-induced hepatotoxicity.

Authors:  Julie Massart; Karima Begriche; Caroline Moreau; Bernard Fromenty
Journal:  J Clin Transl Res       Date:  2017-02-12

7.  Co-exposure to benzo[a]pyrene and ethanol induces a pathological progression of liver steatosis in vitro and in vivo.

Authors:  Simon Bucher; Arnaud Tête; Normand Podechard; Marie Liamin; Dounia Le Guillou; Martine Chevanne; Cédric Coulouarn; Muhammad Imran; Isabelle Gallais; Morgane Fernier; Quentin Hamdaoui; Marie-Anne Robin; Odile Sergent; Bernard Fromenty; Dominique Lagadic-Gossmann
Journal:  Sci Rep       Date:  2018-04-13       Impact factor: 4.379

8.  In vivo assessment of the drug interaction between sorafenib and paracetamol in rats.

Authors:  Agnieszka Karbownik; Katarzyna Sobańska; Tomasz Grabowski; Joanna Stanisławiak-Rudowicz; Anna Wolc; Edmund Grześkowiak; Edyta Szałek
Journal:  Cancer Chemother Pharmacol       Date:  2020-05-11       Impact factor: 3.333

9.  Possible Involvement of Mitochondrial Dysfunction and Oxidative Stress in a Cellular Model of NAFLD Progression Induced by Benzo[a]pyrene/Ethanol CoExposure.

Authors:  Simon Bucher; Dounia Le Guillou; Julien Allard; Grégory Pinon; Karima Begriche; Arnaud Tête; Odile Sergent; Dominique Lagadic-Gossmann; Bernard Fromenty
Journal:  Oxid Med Cell Longev       Date:  2018-07-26       Impact factor: 6.543

Review 10.  Treatments in Covid-19 patients with pre-existing metabolic dysfunction-associated fatty liver disease: A potential threat for drug-induced liver injury?

Authors:  Pierre-Jean Ferron; Thomas Gicquel; Bruno Mégarbane; Bruno Clément; Bernard Fromenty
Journal:  Biochimie       Date:  2020-09-03       Impact factor: 4.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.